Erik Amble

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

Serca Pharmaceuticals AS develops, markets, and sells drug treatment products, medicinal products, and equipment for injuries. The company was founded on October 8, 2018 and is headquartered in Lysaker, Norway.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

Neomed Management AS is an investment firm based in Oslo. Founded in 1998, the firm specializes in private equity investments in the healthcare and life science sectors. Neomed advises several funds namely NeoMed I, II, III, IV and V.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

Serca Pharmaceuticals AS develops, markets, and sells drug treatment products, medicinal products, and equipment for injuries. The company was founded on October 8, 2018 and is headquartered in Lysaker, Norway.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

Serca Pharmaceuticals AS develops, markets, and sells drug treatment products, medicinal products, and equipment for injuries. The company was founded on October 8, 2018 and is headquartered in Lysaker, Norway.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.